Pipeline
Next-Generation Incretin Research After Tirzepatide
Research beyond tirzepatide focuses on triple agonists such as retatrutide, oral small-molecule incretins, and combinations aimed at preserving lean mass. These agents are investigational: they are not approved, not available by prescription for weight management, and any product sold as one outside a clinical trial should be treated as illegitimate.
Key takeaways
- Retatrutide and similar triple agonists are investigational, not approved therapies.
- Oral small-molecule incretins are in development and would change the access picture if approved.
- Lean-mass-preserving combinations are an active research direction.
- Phase 2 results frequently attenuate in phase 3; early numbers should be treated cautiously.
- Any seller offering an investigational agent outside a trial is operating illegitimately.
| Status of retatrutide | Investigational — not FDA approved |
|---|---|
| Main directions | Triple agonists, oral small molecules, lean-mass-preserving combinations |
| Typical attrition | Phase 2 effect sizes commonly shrink in phase 3 |
| Legitimate access | Enrolment in a registered clinical trial only |
| Warning | Products marketed as investigational agents outside trials are not legitimate |
Why should early-phase results be read cautiously?
Because phase 2 trials are smaller, shorter, and enrol more selected populations than phase 3, and effect sizes reliably shrink as trials get larger and more representative. Safety signals that a few hundred participants cannot reveal also emerge at scale. A striking phase 2 headline is a reason to pay attention, not a basis for a treatment decision.
How can someone legitimately access an investigational drug?
Through enrolment in a registered clinical trial, or in narrow circumstances through an expanded-access pathway arranged by a physician with the sponsor. There is no legitimate consumer channel. Any website selling a research peptide for human use is operating outside the regulatory system, and the contents of what it ships are unverifiable.
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Retatrutide and other investigational agents and trials and status, organised around the primary question of next generation weight loss drugs. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Retatrutide and other investigational agents | Covered on this page | Primary evidence |
| Trials and status | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with the registered protocol and the peer-reviewed publication |
What are the limits of what this page can tell you?
Every page on this site rests on a specific primary trial record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the registered protocol and the peer-reviewed publication.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on next generation weight loss drugs.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Is retatrutide available?
No. It is investigational and not approved for weight management.
Is it more effective than tirzepatide?
Early-phase results have drawn attention, but comparisons across trial phases are unreliable and no head-to-head evidence establishes this.
Where can I legitimately get an investigational drug?
Only through a registered clinical trial or a physician-arranged expanded-access pathway.
Are research-peptide sellers legitimate?
No. Products sold that way are outside the regulatory system and their contents are unverifiable.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.